Company intelligence / Profile preview
Kringle Pharma, Inc.
Ibaraki, Osaka, Japankringle-pharma.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 3
01
Overview
Kringle Pharma’s lead program uses recombinant human HGF protein as a regenerative therapy. The company has completed Phase I/II trials showing safety and efficacy signals in acute spinal cord injury with orphan drug designation granted in Japan. A Phase III trial for this indication has been completed with NDA filing planned by end of 2025. Vocal fold scar program is ongoing at Phase III. ALS program had no statistically significant results but further analysis continues. Acute kidney injury program completed early-stage studies confirming safety/pharmacokinetics; seeking partners for further development
- Therapeutic areas
- OtherOphthalmologyNeurologyNephrology
- Modalities
- Recombinant protein therapeutics (specifically recombinant human hepatocyte growth factor [HGF])
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
TOHO HOLDINGS CO., LTD.: Distribution alliance for Japan market regarding HGF-based drugs in acute phase spinal cord injuryClaris Biotherapeutics (ophthalmology clinical collaboration)Capital alliances/investors include Maruishi Pharmaceutical, Resona Capital, Nanto CVC Fund, Yitu Capital, OKB Capital among others
Beyond the preview
Go deeper on Kringle Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kringle Pharma, Inc..